522 results about "Fiber cell" patented technology

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

Certain embodiments here in are directed to a method of treating a tissue associated with a defect in a human including wrinkles, rhytids, depressed scar, cutaneous depressions, stretch marks, hyperplasia of the lip, nasolabial fold, melolabial fold, scarring from acne vulgaris, and post-rhinoplasty irregularity. The tissue defect may be treated by introducing a plurality of in vitro cultured autologous fibroblast cells at or proximal to the defect area of the patient's tissue. The autologous fibroblast cells may have been cultured in vitro to expand the number of fibroblast cells in at least one medium that comprises autologous serum. The autologous fibroblast cell cultures may be derived from connective tissue, dermal, fascial fibroblasts, papillary fibroblasts, and / or reticular fibroblasts.

A cultured skin and a grafting cultured skin sheet are provided, each of which is a cultured reconstructive skin with a high take rate using cells collectable from cells originated from tissue included in an umbilical cord such as tissue included in an umbilical cord originated from a human fetus. The grafting cultured skin stratified sheet is prepared by placing an epithelium sheet on the top surface of a cultured dermis. The cultured dermis includes as components a cultured skin containing cells originated from a tissue included in an umbilical cord, such as umbilical cells, more concretely, umbilical fibroblast cells, being separated and cultured, preferably in a collagen nonwoven fabric. On the other hand, the epithelium sheet is prepared by culturing and stratifying the umbilical cord epithelium cells.

The invention provides a microfabricated device for sorting cells based on a desired characteristic, for example, reporter-labeled cells can be sorted by the presence or level of reporter on the cells. The device includes a chip having a substrate into which is microfabricated at least one analysis unit. Each analysis unit includes a main channel, having a sample inlet channel, typically at one end, and a detection region along a portion of its length. Adjacent and downstream from the detection region, the main channel has a discrimination region or branch point leading to at least two branch channels. The analysis unit may further include additional inlet channels, detection points, branch points, and branch channels as desired. A stream containing cells is passed through the detection region, such that on average one cell occupies the detection region at a given time. The cells can be sorted into an appropriate branch channel based on the presence or amount of a detectable signal such as an optical signal, with or without stimulation, such as exposure to light in order to promote fluorescence.

An absorbable pubovaginal sling system for surgical management of urinary incontinence, generally comprising: a latex-free, synthetic sling made entirely of absorbable materials of which at least one of the materials is adapted to stimulate fibroblast interposition; and a looped monofilament suture that is adapted to be transposed to the suprapubic position, supported by an external adjustable tension device, and connected to said sling.

A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.

A scalable, energy efficient process for preparing cellulose nanofibers is disclosed. The process employs a depolymerizing treatment with one or both of: (a) a relatively high charge of ozone under conditions that promote the formation of free radicals to chemically depolymerize the cellulose fiber cell wall and interfiber bonds; or (b) a cellulase enzyme. Depolymerization may be estimated by pulp viscosity changes. The depolymerizing treatment is followed by or concurrent with mechanical comminution of the treated fibers, the comminution being done in any of several mechanical comminuting devices, the amount of energy savings varying depending on the type of comminuting system and the treatment conditions. Comminution may be carried out to any of several endpoint measures such as fiber length, % fines or slurry viscosity.

The invention relates to a human mesenchymal stem cell culture medium. According to the culture medium, the basal culture medium comprises the following components based on the final concentration: 1-2g / L of human serum albumin, 5-10mg / L of transferring, 2-8mg / L of fibronectin, 1-4mg / L of laminin, 50g / L of Fe(NO3)3.9H2O, 417g / L of FeSO4.7H2O, 1-3mu g / L of estradiol, 2-5mu g / L of testosterone, 1-3mu g / L of progesterone, 39.25-117.74 mu g / L of dexamethasone, 5-10mg / L of insulin, 376.36mg / L of riboflavin, 80.96-242.87mg / L of coenzyme A, 4.41-6.17mg / L of butanediamine, 1-2mg / L of taurine, 0.61-1.85mg / L of aminoethanol, 8.81-26.42mg / L of pyruvic acid, 3.78-7.56mu g / L of sodium selenate, 292.3-584.6mg / L of L-glutamine, 2-8mu g / L of vascular endothelial growth factor, 4-10mu g / L of epidermal growth factor, 4-10mu g / L of basic fibroblast growth factor, 1-5mu g / L of leukaemia inhibitory factor, 1-5mu g / L of insulin-like growth factor-I and 2-8mu g / L of stem cell factor. The culture medium does not contain the animal serum, the potential animal endogenous endotoxin or virus of the animal serum is eliminated, and the culture medium is conveniently applied to clinics.

The described invention provides compositions and methods for preventing or treating a disease, condition, or pathologic process characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The method includes administering a therapeutic amount of a pharmaceutical composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier.

To control cardiac arrhythmias, various conduction-modifying agents include biopolymers, fibroblasts, neurotoxins, and growth factors are introduced either epicardially or endocardially to the fat pads in proximity to the ganglia therein. Any desired technique may be used for injection, including injection from a catheter inserted percutaneously, or direct injection through the epicardial during open heart surgery. Preferably the patient's heart is beating throughout the Injection.

The present invention relates to a population of blood borne mammalian cells that express a unique profile of surface markers that includes certain markers typical of connective tissue fibroblasts, and are referred to herein as "blood-borne mesenchymal cells." In particular, it relates to the isolation, characterization and uses of such blood-borne mesenchymal cells. The cells of the present invention can be distinguished from peripheral blood leukocytes by their distinct size, morphology, cell surface phenotype and biologic activities, and are likewise distinguishable from connective tissue fibroblasts by other surface phenotypic markers. These cells proliferate in culture, and in vivo, as demonstrated in animal models, are capable of migrating into wound sites from the blood. Therefore, such blood-borne mesenchymal cells may have a wide range of applications, including, but not limited to, the promotion of wound healing, tissue remodeling, and for gene therapy.

The invention discloses a fibrous membrane for tissue repair, a manufacturing method thereof, application thereof for the preparation of products for tissue repair, and a product for tissue repair which is made by the fibrous membrane for tissue repair. The fibrous membrane for tissue repair is formed by interweaving cellosilks with the diameter of 10 nanometers-100 micrometers, and is of a porous structure; the filling power is 200-2000 cm<3> / g. According to the fibrous membrane for tissue repair, the conglutination and the proliferation of cells are facilitated, the guide of the cell differentiation is facilitated, the rapid growth of fibrocytes is facilitated, the tight suture between the fibrous membrane and tissue is facilitated, the comfort of a patient is improved, and the occurrence of conditions of patch shrink, infection and conglutination with visceral organs and the like is reduced.

The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.

The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.

A cell or tissue-culturing carrier which can effectively regenerate an intended a cell or tissue, while suppressing an excessive growth of fibroblasts, and a method of culturing a cell or tissue by using the above carrier, the cell or tissue-culturing carrier wherein fibroblasts showing substantially no growing property in a gel based on the hydrogel-forming polymer, is constituted by using a hydrogel-forming polymer; an aqueous solution of which shows a thermo-reversible sol-gel transition such that it assumes a sol state at a lower temperature and assumes a gel state at a higher temperature.

The invention discloses a method for obtaining transgenic bovine fetal fibroblast by using Cas9 cutting nuclease-mediated Ipr1 fixed point insertion. The bovine fetal fibroblast is cotransfected by adonor vector and a CRISPR / Cas0 expression vector for a target locus through an electroporation method, an MSR1 promoter in the donor vector can realize specific expression in full-time phagocytic cells, and after puromycin drug screening, the targeted positive clone cell is obtained through PCR authentication. The transgenic positive clone cell is used as a donor cell so as to obtain a transgenicclone embryo, the transgenic clone embryo is further transplanted into the uterus of a rutting acceptor calf, and finally a living Ipr1 fixed point insertion transgenic cloned calf is obtained.

Textured nanostructured surfaces are described which are highly resistant to cell adhesion. Such surfaces on medical implants inhibit fibroblast adhesion particularly on titanium treated silicone. The surfaces can also be engineered so that other cell types, such as endothelial and osteoblast cells, show little if any tendency to attach to the surface in vivo.

The invention discloses a technique for rapidly extracting ramie hemp erwinia bacterium factory production fermentation, the technique comprises preprocessing material, immersing or sprinkling and inoculating, immersing or fermenting, deactivating with hot water, and the procedure of circulation washing, water dressing and fiber finish, erwinia bacterium which has broad-spectrum and high effective to degumming, pulping and saccharifying of herb fiber material, and bacterial agent preparation and activated technical parameter. The erwinia bacterium addicts the mannose, the peak for secreting non-cellulose to degrade key enzyme (pectic enzyme, beta-mannase and xylanase) can be achieved through purely culturing for 7h to 9h. Bacterial agent is inoculated on herb fiber material such as ramie and the like for activating the bacterial agent for 5h-6h, fermentation forage fodder turns to blue after fermenting for 5h-6h, pectine, hemicellulose and partial lignin which are partially degraded and associated in fiber cell are stripped, non-cellulose residues which are absorbed on fiber can be removed by means of the flushing of high-pressure flushing, and the purpose of extracting net fiber can be reached.

The invention discloses a screw injection type device for vegetation fiber steam-explosion and a method thereof. The device comprises a charging barrel which is internally provided with a squeezing screw rod matching the charging barrel; a feed inlet and a feed outlet are arranged on the charging barrel; a quick opening valve is arranged at the feed outlet; the squeezing screw rod is driven by a driving mechanism; an advancing mechanism is arranged at the rear end of the squeezing screw rod and a temperature controller is arranged on the charging barrel. The invention can respectively control the explosion pressure, the temperature and the retention time and has better suitability; therefore, while fiber cell separation is realized by vegetation fiber steam-explosion, modifying agent can be added in to realize in-situ modification of vegetation fiber, thus satisfying diverse application requirements of vegetation fiber.

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.

The invention discloses a device for in vitro high-density cultivation of erythrocyte. The device comprises a stirred tank bioreactor and a hollow fiber cell intercepting device, wherein the structure of the hollow fiber cell intercepting device includes a cylindrical sleeve formed by 4-10 hollow fiber tubes which are parallel to one another; an elastic valve, a piston and a vacuum pump are orderly arranged at the bottom of the cylindrical sleeve; and the upper part of the cylindrical sleeve is connected with the stirred tank bioreactor through a connecting pipe. A method for in vitro high-density cultivation of erythrocyte is also disclosed by the invention. The method comprises the following steps of (1) separating a mononuclear cell; (1) separating CD34+ hematopoietic stem cell; and (3) differentiating the hematopoietic stem cell into the erythrocyte. By using the device and the method, hematopoietic stem cells with different sources can be utilized to carry out in vitro differentiation, so as to form a lot of erythrocytes with complete functions. High-density cultivation of the erythrocytes can be achieved; and the density is improved by about 200 times in comparison with a common cell cultivation method.

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

The embodiments herein disclose a method of fabricating composite scaffolds for skin tissue regeneration. The methacrylated hyaluronic acid (HAMA) and methacrylated gelatin (GelMA) are synthesized. The poly (glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) microfibrous scaffolds are synthesized. The hydrogel is synthesized. The composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) microfibrous scaffolds is fabricated. A plurality of physico-chemical characteristics of the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) microfibrous scaffolds are analysed. The physico-chemical characteristics comprises mechanical properties, swelling ratio and enzymatic degradation and scanning electron microscope imaging. The fibroblast cells are encapsulated within the composite scaffold comprising hydrogel and poly (glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) microfibrous scaffolds and hydrogels. The fibroblast cells are seeded on composite scaffold and PGS-PCL scaffold. The fibroblast cell viability, fibroblast cell attachment, fibroblast cell spreading, fibroblast cell proliferation and fibroblast cell metabolism are analysed in composite scaffolds, PGS-PCL scaffolds and hydrogels.

The invention relates to the use of a Fibroblast Growth Factor 21 (FGF21 ) compound and a Glucagon-Like Peptide 1 (GLP-1 ) compound in combination for the preparation of a medicament for the treatment of diabetes, more in particular type 2 diabetes, as well as pharmaceutical compositions comprising certain FGF21 and GLP-1 compounds in combination, together with a pharmaceutically acceptable carrier. The combination has a significant effect on parameters of relevance for diabetes type 2, viz. on the viability of [beta] cells ex vivo in the presence of free fatty acids, on caspase activity of [beta] cells ex vivo (a measure of cell apoptosis), and a blood glucose lowering effect on db / db mice in vivo.

The invention discloses a method for testing lignification degrees of plant cell walls based on a confocal Raman microscopic technology. The method comprises the following steps of: testing Raman spectrums of the plant cell walls under the in-situ state by using a confocal Raman microscope to obtain Raman spectrum imaging graphs of lignin in the cell walls; and determining the content of the lignin in the cell walls according to Raman signal intensities, and determining the lignification degrees of different secondary cell walls and different form areas of fiber cell walls. The testing method is based on a pure spectrum method, samples are quickly prepared, chemical pollutants are not generated, and the information of the lignification degrees of the plant cell walls can be acquired under the in-situ state.

The invention relates to a conductive parallel fiber membrane which is capable of promoting rapid repair of peripheral nervous tissues and is connected to an extracellular matrix, wherein the thin film (the fiber membrane) can serve as a biofunctional nerve scaffold. The conductive parallel fiber membrane which is connected to the extracellular matrix and is of a core-shell structure is prepared by virtue of a three-step method, namely preparing parallel fibers through electrostatic spinning, covering conductive polypyrrole through electrochemical oxidation, and conducting human skin fibroblast culture and splitting cells by virtue of a triton x-100 / ammonia water mixed solution. According to the invention, the composite fiber membrane, by virtue of the parallel structure, can guide the growth of nerve fibers in a directional mode, by virtue of the extracellular matrix, adhesion of the nerve cells and axon thereof is improved, and by virtue of the conductive polymer (the conductive polypyrrole), the growth of the nerve axon is promoted through electric stimulation; and with a synergistic effect among the three means, the regeneration and repair of nerves are promoted. A preparation device adopted by the invention is simple and easy, simple to operate, wide in material source and low in cost; and the prepared nerve scaffold is good in biocompatibility and functionality, and the nerve scaffold is expected to be applied to clinical field in the future.

A human corneal limbal stem cell-amnion tissue engineering complex using human corneal limbal fibroblasts as the trophoblast is characterized in that: it is close to the human corneal epithelium form in histology form, and is analogous to the human corneal epithelium in immunology phenotype, its ultrastructure shows that the connection between the cells grows mature and the connection between the epithelia and the amnion carrier is a close conglutination. The culture method includes the following steps: (1) preparing the amnion for culturing the human corneal limbal stem cell in vitro; (2) preparing the human corneal limbal fibroblast trophoblast; (3) preparing the human corneal epithelia suspension; (4) culturing the human corneal limbal stem cell-amnion complex. The human corneal limbal stem cell-amnion complex has analogous phenotype to the human corneal epithelium, and provides a safe and effective biology tissue engineering product to treat corneal limbal stem cell defective eye diseases.

The invention relates to a rh-bFGF gel and the making method that is a drug used to cure wound, canker, scald, and burn. It is compounded by 146 amino acids. The main drug is rh-bFGF, and gel basal material includes thickener, humectant, antiseptic, stabilizer, pH regulator, and water. The manufacture method includes the following steps: mixing the thickener, humectant, antiseptic, stabilizer, pH regulator, and water according to certain ratio, whisking to equal to make water solubility gel basal material, adding rh-bFGF after high pressure sterilization, mixing equally to make gel and separately packaging into aluminum mold tube to make drug using rh-bFGF gel products.